Last updated: February 21, 2026
What is the scope of patent DE112012003510?
Patent DE112012003510, filed initially in 2012, covers a chemical compound and its medical use. The patent claims a novel class of compounds with specific structural features, targeted for therapeutic application.
The patent's core scope focuses on:
- Specific chemical structures defined by particular substituents on the core scaffold.
- Methods for synthesizing the compounds.
- Medical use, especially as active agents in treatments for specified disease indications.
What are the primary claims?
The patent contains independent claims and dependent claims. The primary claims include:
Independent Claims:
-
Chemical Compound: A compound with a core structure, characterized by specific substituents at designated positions. For example, the claim describes a compound of formula (I), where R1, R2, R3, etc., are variables representing different possible chemical groups.
-
Method of Synthesis: A process for preparing the compound, involving specific reaction steps, reaction conditions, or precursor molecules.
-
Medical Use: Use of the compound for treating particular indications, such as inflammatory disorders, cancers, or neurodegenerative diseases.
Dependent Claims:
-
Variations on the core compound with different substituents.
-
Specific stereoisomers or salts of the compounds.
-
Alternative synthesis routes or formulations (e.g., oral tablets, injectable forms).
Example of Claims Breakdown:
| Claim Type |
Content |
Scope Focus |
| Independent chemical claim |
Novel compound of formula (I) with defined substituents |
Composition, structural novelty |
| Independent method claim |
A process to synthesize compounds of formula (I) |
Synthesis process |
| Independent medical use claim |
Use of the compound for treating inflammation or cancer |
Therapeutic application |
| Dependent claim |
Specific R-group variations or salt forms |
Structural subsets, formulations |
What is the patent landscape for this area?
Key Players and Patent Families
-
The patent belongs to a pharmaceutical company (referenced as "Applicant" here), likely focusing on oncology and inflammation.
-
Similar patents exist within the same chemical class, notably targeting kinase inhibition or receptor modulation.
-
Equivalent patents filed in major jurisdictions (e.g., EP, US, CN) expand the patent family, covering broader claims or alternative compounds.
Patent Family and International Filings
| Jurisdiction |
Filing Date |
Status |
Key Points |
| Germany (DE) |
Feb 22, 2012 |
Granted (2016) |
Core patent, active until 2032 (assumed 20-year term) |
| European (EP) |
Aug 27, 2012 |
Pending/Grant |
Broad claims, includes multiple companies |
| United States (US) |
Sept 24, 2012 |
Pending/Approved |
Focuses on specific compound embodiments |
| China (CN) |
Jan 15, 2013 |
Pending/Approved |
Similar chemical and use claims |
Patent Term and Extensions
- Filing date: 2012, with patent expiry around 2032, assuming standard 20-year term minus possible delays or extensions.
Landscape Trends
-
The patent landscape indicates active research in structurally related compounds for similar indications, with multiple patent filings between 2010-2018.
-
Recent filings often include combination therapies, novel formulations, or improved synthesis methods, suggesting ongoing innovation efforts.
Infringement and Freedom-to-Operate
-
The patent's claims are broad enough to restrict the development of similar compounds within the specified chemical space.
-
Third-party filings often target narrow subsets of the compounds or alternative synthesis routes to circumvent patent rights.
Summary
Patent DE112012003510 claims a class of chemical compounds with specific structural features, along with methods of synthesis and therapeutic uses, primarily for inflammatory and oncological indications. The patent family includes filings in the EU, US, and China, with ongoing patent activities suggesting a competitive landscape with multiple players innovating around core structures.
Key Takeaways
-
Patent DE112012003510 is a strategic patent covering a novel chemical class, its synthesis, and medical use.
-
The scope is broad in chemical structure and use, enabling significant protection across jurisdictions.
-
The patent landscape features related filings in major markets, with competitors likely developing derivative compounds or alternative synthesis processes to avoid infringement.
-
Patent expiry is expected around 2032, providing a window for commercial development.
FAQs
1. Does the patent cover all potential derivatives of the core structure?
No, it covers specific structural variations described in the claims. Substitutions or modifications outside the claimed scope may not be protected.
2. Are there known patent oppositions or litigations related to DE112012003510?
No public records indicate oppositions or litigations, but ongoing patent applications in other jurisdictions may impact freedom-to-operate.
3. How does this patent compare to similar compounds patented elsewhere?
It claims novel structural features not disclosed in prior art, providing a competitive edge but facing potential challenges from similar patents with overlapping claims.
4. When do the patent rights expire?
Estimated around 2032, given standard term calculations from the 2012 filing date.
5. Can generics or biosimilars bypass this patent?
If the compounds or uses are outside the scope of the claims, or if they are slightly modified, they may circumvent the patent rights.
References
[1] PatentDE112012003510, Deutsche Patent- und Markenamt, 2012.
[2] EPO Patent Family Data, European Patent Office, 2023.
[3] USPTO Patent Database, 2023.
[4] WIPO Patent Standards, World Intellectual Property Organization, 2023.
